Dual antiplatelet therapy (DAPT) with indobufen and clopidogrel — compared with DAPT using aspirin and clopidogrel — significantly lowered the risk of 1-year bleeding risk without increasing ischemic events in Chinese patients with negative cardiac troponin undergoing drug-eluting stent (DES) implantation, new trial results show.